Comparative Pharmacology
Head-to-head clinical analysis: SCLEROSOL versus SODIUM TETRADECYL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCLEROSOL versus SODIUM TETRADECYL SULFATE.
SCLEROSOL vs SODIUM TETRADECYL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
0.5-5 mL of 5% solution administered by intrapleural injection once daily for up to 3 days.
1% to 3% solution, 0.1-0.5 mL per injection, intravenous, as needed for sclerotherapy; maximum 10 mL per session.
None Documented
None Documented
60-90 minutes (clinical context: rapid elimination requires multiple daily dosing for maintenance of effect)
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Primarily renal (80-90% unchanged), minimal biliary/fecal (5-10%)
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Category C
Category C
Sclerosing Agent
Sclerosing Agent